Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals
© 2024 Boston et al..
Bidirectional interactions between the immune system and the gut microbiota are key contributors to various physiological functions. Immune-associated diseases such as cancer and autoimmunity, and efficacy of immunomodulatory therapies, have been linked to microbiome variation. Although COVID-19 infection has been shown to cause microbial dysbiosis, it remains understudied whether the inflammatory response associated with vaccination also impacts the microbiota. Here, we investigate the temporal impact of COVID-19 vaccination on the gut microbiome in healthy and immuno-compromised individuals; the latter included patients with primary immunodeficiency and cancer patients on immunomodulating therapies. We find that the gut microbiome remained remarkably stable post-vaccination irrespective of diverse immune status, vaccine response, and microbial composition spanned by the cohort. The stability is evident at all evaluated levels including diversity, phylum, species, and functional capacity. Our results indicate the resilience of the gut microbiome to host immune changes triggered by COVID-19 vaccination and suggest minimal, if any, impact on microbiome-mediated processes. These findings encourage vaccine acceptance, particularly when contrasted with the significant microbiome shifts observed during COVID-19 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Life science alliance - 7(2024), 4 vom: 04. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boston, Rebecca H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.02.2024 Date Revised 10.02.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.26508/lsa.202302529 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368057267 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368057267 | ||
| 003 | DE-627 | ||
| 005 | 20240210233225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26508/lsa.202302529 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM368057267 | ||
| 035 | |a (NLM)38316462 | ||
| 035 | |a (PII)e202302529 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boston, Rebecca H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Boston et al. | ||
| 520 | |a Bidirectional interactions between the immune system and the gut microbiota are key contributors to various physiological functions. Immune-associated diseases such as cancer and autoimmunity, and efficacy of immunomodulatory therapies, have been linked to microbiome variation. Although COVID-19 infection has been shown to cause microbial dysbiosis, it remains understudied whether the inflammatory response associated with vaccination also impacts the microbiota. Here, we investigate the temporal impact of COVID-19 vaccination on the gut microbiome in healthy and immuno-compromised individuals; the latter included patients with primary immunodeficiency and cancer patients on immunomodulating therapies. We find that the gut microbiome remained remarkably stable post-vaccination irrespective of diverse immune status, vaccine response, and microbial composition spanned by the cohort. The stability is evident at all evaluated levels including diversity, phylum, species, and functional capacity. Our results indicate the resilience of the gut microbiome to host immune changes triggered by COVID-19 vaccination and suggest minimal, if any, impact on microbiome-mediated processes. These findings encourage vaccine acceptance, particularly when contrasted with the significant microbiome shifts observed during COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Guan, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Kalmar, Lajos |e verfasserin |4 aut | |
| 700 | 1 | |a Beier, Sina |e verfasserin |4 aut | |
| 700 | 1 | |a Horner, Emily C |e verfasserin |4 aut | |
| 700 | 1 | |a Beristain-Covarrubias, Nonantzin |e verfasserin |4 aut | |
| 700 | 1 | |a Yam-Puc, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Pereyra Gerber, Pehuén |e verfasserin |4 aut | |
| 700 | 1 | |a Faria, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroshchenkova, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Lindell, Anna E |e verfasserin |4 aut | |
| 700 | 1 | |a Blasche, Sonja |e verfasserin |4 aut | |
| 700 | 1 | |a Correa-Noguera, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Elmer, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Bermperi, Areti |e verfasserin |4 aut | |
| 700 | 1 | |a Jose, Sherly |e verfasserin |4 aut | |
| 700 | 1 | |a Kingston, Nathalie |e verfasserin |4 aut | |
| 700 | 0 | |a CITIID-NIHR COVID-19 BioResource Collaboration |e verfasserin |4 aut | |
| 700 | 1 | |a Grigoriadou, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Staples, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Buckland, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Lear, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Matheson, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Benes, Vladimir |e verfasserin |4 aut | |
| 700 | 1 | |a Parkinson, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Thaventhiran, James Ed |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Kiran R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life science alliance |d 2018 |g 7(2024), 4 vom: 04. Feb. |w (DE-627)NLM286067536 |x 2575-1077 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:4 |g day:04 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26508/lsa.202302529 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 4 |b 04 |c 02 | ||